Rintatolimod

Drug Profile

Rintatolimod

Alternative Names: Ampligen; Mismatched double-stranded RNA - Hemispherx Biopharma; Poly I:Poly C12U; Poly I:polyC12U; poly(I) poly(C12,U); Rintamod

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Hemispherx Biopharma
  • Developer Hemispherx Biopharma; United States Army Medical Research Institute of Infectious Diseases; University of Pittsburgh
  • Class Adjuvants; Antivirals; Nucleotides; RNA
  • Mechanism of Action Interferon stimulants; RNA synthesis inhibitors; Toll-like receptor 3 agonists; VP35 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Ebola virus infections; HIV infections; Chronic fatigue syndrome; Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Chronic fatigue syndrome
  • Phase I/II Breast cancer; Colorectal cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Ebola virus infections; West Nile virus infections; Zika virus infection
  • Research Alphavirus infections; Coronavirus infections; Influenza A virus infections
  • Suspended HIV infections
  • No development reported Hepatitis B; Malignant melanoma; Renal cell carcinoma
  • Discontinued Smallpox; Western equine encephalitis virus infections

Most Recent Events

  • 11 Jan 2017 European Early access programme for rintatolimod has been extended to include pancreatic cancer patients
  • 31 Oct 2016 Updated retrospective analysis of efficacy data from a phase III trial in Chronic fatigue syndrome released by Hemispherx Biopharma
  • 31 Oct 2016 Hemispherx Biopharma plans a confirmatory phase III trial for Chronic fatigue syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top